Overview

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly called nonalcoholic fatty liver disease (NAFLD), is a liver condition that affects people with excess weight, obesity or other metabolic conditions, such as type 2 diabetes, high blood pressure or high cholesterol. In MASLD, too much fat builds up in the liver.

MASLD is becoming more common, especially in Middle Eastern and Western nations, as the number of people with obesity rises. It is the most common form of liver disease in the world. MASLD ranges in severity from hepatic steatosis — sometimes called diffuse hepatic steatosis, or formerly fatty liver infiltration or simply fatty liver — to a more severe form of disease called metabolic dysfunction-associated steatohepatitis (MASH), formerly called nonalcoholic steatohepatitis (NASH).

MASH causes the liver to swell or enlarge. This is known as hepatomegaly. MASH also causes fat deposits in the liver, which causes liver damage. MASH may get worse and may lead to serious liver scarring, called cirrhosis, or even liver cancer. This damage is like the damage caused by heavy alcohol use.

Life expectancy varies depending on whether you have MASLD or MASH. Factors such as scarring and other health conditions also affect how long you can live with MASLD or MASH.

Symptoms

MASLD often has no symptoms. When it does, they include:

  • Feeling very tired, also called fatigue.
  • Not feeling well, known as malaise.
  • Pain or discomfort in the upper right belly area.

Possible symptoms of MASH and cirrhosis, which is severe scarring, include:

  • Itchy skin.
  • Abdominal swelling, also called ascites (uh-SY-teez).
  • Shortness of breath.
  • Swelling in the legs.
  • Spiderlike blood vessels just beneath the skin's surface.
  • Enlarged spleen.
  • A change in skin color on the palms.
  • Yellowing of the skin and eyes, also called jaundice.

When to see a doctor

Make an appointment with a member of your health care team if you have lasting symptoms that worry you.

Get the latest health information from Mayo Clinic delivered to your inbox.

Subscribe for free and receive your in-depth guide to digestive health, plus the latest on health innovations and news. You can unsubscribe at any time. Click here for an email preview.

We use the data you provide to deliver you the content you requested. To provide you with the most relevant and helpful information, we may combine your email and website data with other information we have about you. If you are a Mayo Clinic patient, we will only use your protected health information as outlined in our Notice of Privacy Practices. You may opt out of email communications at any time by clicking on the unsubscribe link in the email.

Causes

Experts don't know exactly why fat builds up in some livers and not others. They also don't fully understand why fat buildup in some livers turns into MASH.

MASLD and MASH are both linked to the following:

  • Genetics.
  • Being overweight or having obesity.
  • Insulin resistance, which happens when the body's cells don't take up sugar in response to the hormone insulin.
  • Type 2 diabetes, sometimes called high blood sugar or hyperglycemia.
  • High levels of fats, especially triglycerides, in the blood.

These combined health concerns may contribute to liver damage. However, some people get MASLD even if they do not have any risk factors.

Risk factors

Many diseases and health conditions can increase your risk of MASLD, including:

  • Obesity, especially when fat is centered in the waist.
  • Type 2 diabetes.
  • High cholesterol.
  • High levels of triglycerides in the blood.
  • Insulin resistance.
  • Metabolic syndrome.
  • Polycystic ovary syndrome.
  • Obstructive sleep apnea.
  • Underactive thyroid, also called hypothyroidism.
  • Underactive pituitary gland, also called hypopituitarism.
  • Growth hormone deficiency, which means the body doesn't make enough hormones to grow.

MASH is more likely in people:

  • Older than 50.
  • Who have certain genetic risk factors.
  • With obesity.
  • With diabetes or high blood sugar.
  • With symptoms of metabolic syndrome, such as high blood pressure, high triglycerides and a large waist size.

It is hard to tell MASLD and MASH apart without an exam and testing.

Complications

Severe liver scarring, also called cirrhosis, is the main complication of MASLD and MASH. Cirrhosis happens because of liver injury, such as the damage caused by inflammation in MASH. As the liver tries to stop inflammation, it creates areas of scarring, also called fibrosis. With ongoing inflammation, fibrosis spreads and takes up more liver tissue.

If nothing is done to stop the scarring, cirrhosis can lead to:

  • Fluid buildup in the stomach area, called ascites.
  • Swollen veins in the esophagus, called esophageal varices, which can rupture and bleed.
  • Confusion, sleepiness and slurred speech, also called hepatic encephalopathy.
  • Overactive spleen, known as hypersplenism, which can cause too few blood platelets.
  • Liver cancer.
  • End-stage liver failure, which means the liver has stopped working.

For many people with MASLD, the outlook is good, especially if they make recommended lifestyle changes. In fact, in some people, weight loss may help reverse MASLD. However, some people develop MASH, which significantly impacts life expectancy and health outcomes.

Prevention

To reduce your risk of MASLD:

  • Eat a healthy diet. Eat a diet that's rich in fruits, vegetables, whole grains and healthy fats. One such diet is the Mediterranean diet.
  • Limit alcohol, simple sugars and portion sizes. Avoid sugary drinks such as soda, sports drinks, juices and sweet tea. Avoid or limit alcohol, which can damage the liver.
  • Keep a healthy weight. If you are overweight or have obesity, work with your healthcare team to gradually lose weight. If you are at a healthy weight, work to keep it by eating a healthy diet and exercising.
  • Exercise. Be active most days of the week. Get an OK from your healthcare team first if you haven't been exercising regularly.

Oct. 14, 2025

Living with nonalcoholic fatty liver disease?

Connect with others like you for support and answers to your questions in the Transplants support group on Mayo Clinic Connect, a patient community.

Transplants Discussions

Lori, Volunteer Mentor
Snapshots of hope: Life on the other side of transplant.

110 Replies Thu, Sep 25, 2025

rwilliams1152
Liver transplant cancelled: Am I back to the top of the list?

9 Replies Fri, Sep 12, 2025

lmctif
Liver transplant - Let's support each other

1688 Replies Fri, Aug 08, 2025

See more discussions
  1. Cusi K, et al. American Association of Clinical Endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: Co-sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocrine Practice. 2022; doi:10.1016/j.eprac.2022.03.010.
  2. Nonalcoholic fatty liver disease (NAFLD). American Liver Foundation. https://liverfoundation.org/liver-diseases/fatty-liver-disease/nonalcoholic-fatty-liver-disease-nafld. Accessed May 11, 2023.
  3. Nonalcoholic fatty liver disease (NAFLD) and NASH. National Institute of Diabetes and Digestive and Kidney Diseases. https://www.niddk.nih.gov/health-information/liver-disease/nafld-nash. Accessed May 11, 2023.
  4. Sheth SG, et al., eds. Epidemiology, clinical features, and diagnosis of nonalcoholic fatty liver disease in adults. https://www.uptodate.com/contents/search. Accessed May 11, 2023.
  5. Elsevier Point of Care. Clinical Overview: Nonalcoholic fatty liver disease. https://www.clinicalkey.com. Accessed May 11, 2023.
  6. Chen YP, et al. A systemic review and a dose-response meta-analysis of coffee dose and nonalcoholic fatty liver disease. Clinical Nutrition. 2018. doi:10.1016/j.clnu.2018.11.030.
  7. Ludwig J, et al. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clinic Proceedings. 1980; doi:10.1016/S0025-6196(24)00530-5.
  8. Nonalcoholic fatty liver disease (NAFLD). Merck Manual Professional Version. https://www.merckmanuals.com/professional/hepatic-and-biliary-disorders/approach-to-the-patient-with-liver-disease/nonalcoholic-fatty-liver-disease-nafld. Accessed May 11, 2023.
  9. Malhi H, et al. Nonalcoholic fatty liver: Optimizing pretransplant selection and posttransplant care to maximize survival. Current Opinion in Organ Transplantation. 2016. doi:10.1097/MOT.0000000000000283.
  10. Heimbach JK, et al. Combined liver transplantation and gastric sleeve resection for patients with medically complicated obesity and end-stage liver disease. American Journal of Transplantation. 2013. doi:10.1111/j.1600-6143.2012.04318.x.
  11. Cho JH, et al. The clinical and metabolic effects of intragastric balloon on morbid obesity and its related comorbidities. Clinical Endoscopy. 2021. doi:10.5946/ce.2020.302.
  12. AskMayoExpert. Nonalcoholic fatty liver disease (adult). Mayo Clinic; 2022.
  13. Thomas RA. Allscripts EPSi. Mayo Clinic. May 25, 2023.
  14. Medical review (expert opinion). Mayo Clinic. June 20, 2023.
  15. Rinella ME, et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. Journal of Hepatology. 2023; doi:10.1016/j.jhep.2023.06.003.
  16. Rezdiffra (approval letter). New Drug Application 217785. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217785. Accessed March 29, 2024.
  17. Teng ML, et al. Global incidence and prevalence of nonalcoholic fatty liver disease. Clinical and Molecular Hepatology. 2023; doi:10.3350/cmh.2022.0365.
  18. Medical review (expert opinion). Mayo Clinic. Sept. 22, 2025.
  19. Targher G, et al. Metabolic dysfunction–associated steatotic liver disease. New England Journal of Medicine. 2025; doi:10.1056/NEJMra2412865.
  20. Zhang GY, et al. A clinical update on MASLD. JAMA Internal Medicine. 2025; doi:10.1001/jamainternmed.2024.6431. PMID: 39585671.
  21. Shang Y, et al. Risk of cardiovascular disease and loss in life expectancy in NAFLD. Hepatology. 2022; doi:10.1002/hep.32519.
  22. Yanai H, et al. Metabolic-dysfunction-associated steatotic liver disease — its pathophysiology, association with atherosclerosis and cardiovascular disease, and treatments. International Journal of Molecular Science. 2023; doi:10.3390/ijms242015473.
  23. Chhatwal J, et al. Analysis of a simulation model to estimate long-term outcomes in patients with nonalcoholic fatty liver disease. JAMA Network Open. 2022; doi:10.1001/jamanetworkopen.2022.30426.
  24. Alpízar Salazar M, et al. Natural history of metabolic dysfunction-associated steatotic liver disease: From metabolic syndrome to hepatocellular carcinoma. Medicina (Kaunas). 2025; doi:10.3390/medicina61010088.
  25. Metabolic associated steatotoic liver disease (MASLD): Biomarkers, screening & treatment. Video. Mayo Clinic; 2023. https://educationmedia.mayo.edu/media/Metabolic%20Associated%20Steatotoic%20Liver%20Disease%20%28MASLD%29%3A%20Biomarkers%2C%20Screening%20%26%20Treatment/1_b0gtirjm. Accessed Sept. 22, 2025.
  26. Kamioka H, et al. Low geriatric nutritional risk index predicts poor prognosis in patients with cirrhosis: A retrospective study. Frontiers in Nutrition. 2023; doi:10.3389/fnut.2023.1269399.
  27. Brandão ABM, et al. Performance of six predictive models of death of patients hospitalized for decompensated cirrhosis: a multicenter study. Arquivos de Gastroenterologia. 2025; doi:10.1590/s0004-2803.24612024-065.
  28. Zahoor F, et al. Association of metabolic dysfunction-associated steatotic liver disease/non-alcoholic fatty liver disease with Type 2 diabetes mellitus: A case-control study in a tertiary care hospital in Pakistan. Cureus. 2023; doi:10.7759/cureus.47240.
  29. Danpanichkul P, et al. Increased MASH-associated liver cancer in younger demographics. Hepatology Communications. 2025; doi:10.1097/HC9.0000000000000629.
  30. Guimarães JSF, et al. Burden of liver disease in Brazil, 1996-2022: A retrospective descriptive study of the epidemiology and impact on public healthcare. Lancet Regional Health Americas. 2024; doi:10.1016/j.lana.2024.100731.